Abstract
Dendritic cells (DCs), instructed by the priming signals from microbial factors, can produce interleukin (IL)- 12p70 and promote T helper (Th)1 proliferation and interferon (IFN)-γ production. This event seems to be critical for the containment of infections caused by intracellular pathogens, even including Leishmania infection. In the present in vitro study we have investigated: 1) phagocytic capacities and IL-12 production by human monocyte-derived DCs and macrophages (Mφs), infected with Leishmania infantum promastigotes; 2) IFN-γ production by human CD4+ T cells coincubated with DCs or macrophages pulsed with live promastigotes. Monocyte-derived myeloid DCs and Mφs from healthy donors were infected with live metacyclic Leishmania infantum (MON-1) promastigotes, previously opsonized with 5% autologous serum, at 1:4 cell/parasite ratio. Percentage and index of phagocytosis were calculated after 2, 24 and 48 h of incubation. IL-12 production was evaluated by an ELISA in supernatants from 48 h Leishmania-infected or lipopolysaccharides (LPS)-stimulated DCs and Mφs, also in the presence of phytohemagglutinin-activated or inactivated CD4+ T cells. For IFN-γ production, CD4+ T cells were repeatedly stimulated with DCs or Mφs, pulsed with live Leishmania promastigotes or activated with LPS. The number of IFN-γ-secreting cells was evaluated by an ELISpot assay. Results showed that Mφs have a higher phagocytic capacity towards L. infantum promastigotes than DCs. Moreover, unlike Mφs, Leishmania-infected DCs were able to release IL-12p70; this production significantly increased in the presence of activated CD4+ T cells. Finally, DCs pulsed with live parasites and added to autologous CD4+ T cells induced a higher number of IFN- γ-secreting cells than Mφs, thus indicating their ability to polarize Th cells toward the Th1 subset. These data indicate that DCs are able to promote protective Th1 immune responses in our experimental model of Leishmania infantum infection, thus representing the grounds for initiating immunoterapeutic and vaccinal strategies.
Keywords: Leishmania, IL-12, phagocytosis, Lymphocytes, interferon
Current Pharmaceutical Design
Title: Toll-Like Receptor-Positive Cells and Recognition of Pathogens: How Human Myeloid Dendritic Cells Respond to In Vitro Infection with Leishmania infantum
Volume: 12 Issue: 32
Author(s): Maria Pepe, Maria Altamura, Rosa Spinelli, Rosa Calvello, Matteo Saccia, Pasqua Cavallo, Vito Covelli, Emilio Jirillo and Olga Brandonisio
Affiliation:
Keywords: Leishmania, IL-12, phagocytosis, Lymphocytes, interferon
Abstract: Dendritic cells (DCs), instructed by the priming signals from microbial factors, can produce interleukin (IL)- 12p70 and promote T helper (Th)1 proliferation and interferon (IFN)-γ production. This event seems to be critical for the containment of infections caused by intracellular pathogens, even including Leishmania infection. In the present in vitro study we have investigated: 1) phagocytic capacities and IL-12 production by human monocyte-derived DCs and macrophages (Mφs), infected with Leishmania infantum promastigotes; 2) IFN-γ production by human CD4+ T cells coincubated with DCs or macrophages pulsed with live promastigotes. Monocyte-derived myeloid DCs and Mφs from healthy donors were infected with live metacyclic Leishmania infantum (MON-1) promastigotes, previously opsonized with 5% autologous serum, at 1:4 cell/parasite ratio. Percentage and index of phagocytosis were calculated after 2, 24 and 48 h of incubation. IL-12 production was evaluated by an ELISA in supernatants from 48 h Leishmania-infected or lipopolysaccharides (LPS)-stimulated DCs and Mφs, also in the presence of phytohemagglutinin-activated or inactivated CD4+ T cells. For IFN-γ production, CD4+ T cells were repeatedly stimulated with DCs or Mφs, pulsed with live Leishmania promastigotes or activated with LPS. The number of IFN-γ-secreting cells was evaluated by an ELISpot assay. Results showed that Mφs have a higher phagocytic capacity towards L. infantum promastigotes than DCs. Moreover, unlike Mφs, Leishmania-infected DCs were able to release IL-12p70; this production significantly increased in the presence of activated CD4+ T cells. Finally, DCs pulsed with live parasites and added to autologous CD4+ T cells induced a higher number of IFN- γ-secreting cells than Mφs, thus indicating their ability to polarize Th cells toward the Th1 subset. These data indicate that DCs are able to promote protective Th1 immune responses in our experimental model of Leishmania infantum infection, thus representing the grounds for initiating immunoterapeutic and vaccinal strategies.
Export Options
About this article
Cite this article as:
Pepe Maria, Altamura Maria, Spinelli Rosa, Calvello Rosa, Saccia Matteo, Cavallo Pasqua, Covelli Vito, Jirillo Emilio and Brandonisio Olga, Toll-Like Receptor-Positive Cells and Recognition of Pathogens: How Human Myeloid Dendritic Cells Respond to In Vitro Infection with Leishmania infantum, Current Pharmaceutical Design 2006; 12 (32) . https://dx.doi.org/10.2174/138161206778743556
DOI https://dx.doi.org/10.2174/138161206778743556 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Alpha-1 Antitrypsin: It’s Role in Health and Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Approaches and Resources for Prediction of the Effects of Non-Synonymous Single Nucleotide Polymorphism on Protein Function and Interactions
Current Pharmaceutical Biotechnology Androstenediol Modulates Sepsis Induced Alterations of Survival and Immune Functions in a Murin Model of Sepsis
Medicinal Chemistry Nitroimidazole Radiopharmaceuticals in Hypoxia: Part II Cytotoxicity and Radiosensitization Applications
Current Radiopharmaceuticals Immunology of VIP: A Review and Therapeutical Perspectives
Current Pharmaceutical Design Counter-regulatory ‘Renin-Angiotensin’ System-based Candidate Drugs to Treat COVID-19 Diseases in SARS-CoV-2-infected Patients
Infectious Disorders - Drug Targets Mechanisms to Inhibit Matrix Metalloproteinase Activity: Where are we in the Development of Clinically Relevant Inhibitors?
Recent Patents on Anti-Cancer Drug Discovery Consequences of Aberrant Insulin Regulation in the Brain: Can Treating Diabetes be Effective for Alzheimers Disease
Current Neuropharmacology Prevention of Macrovascular Disease in Type 2 Diabetic Patients: Blockade of the Renin-Angiotensin-Aldosterone System
Current Diabetes Reviews Alpha-1 Antitrypsin Deficiency: Current Perspective from Genetics to Diagnosis and Therapeutic Approaches
Current Medicinal Chemistry Update on the Treatment of Childhood Asthma
Current Pediatric Reviews New Biological Insights in the Immunomodulatory Effects of Mucosal Polybacterial Vaccines in Clinical Practice
Current Pharmaceutical Design GPR40 Carboxylic Acid Receptor Family and Diabetes: A New Drug Target
Current Drug Targets Recent Clinical Evidence for the Treatment of Osteoarthritis: What we have Learned
Reviews on Recent Clinical Trials Advances in the Immune Pathogenesis and Treatment of Multiple Sclerosis
Central Nervous System Agents in Medicinal Chemistry Hypersensitivity to Vitamins with a Focus on Immediate-Type Reactions: Food or Drug Allergy?
Endocrine, Metabolic & Immune Disorders - Drug Targets Inhibition of microRNA-155 Alleviates Neurological Dysfunction Following Transient Global Ischemia and Contribution of Neuroinflammation and Oxidative Stress in the Hippocampus
Current Pharmaceutical Design Prevention of Contrast Induced Nephropathy
Current Drug Therapy Apoptosis Induction by Thalidomide: Critical for Limb Teratogenicity but Therapeutic Potential in Idiopathic Pulmonary Fibrosis?
Current Molecular Pharmacology Neuroprotective Effects of an Erythropoietin-Derived Peptide in PC1 2 Cells under Oxidative Stress
CNS & Neurological Disorders - Drug Targets